Find A Clinical Trial

Disease Type: Esophageal/Gastric

Trial ID D910GC00001
Sponsor ID Matterhorn

A Randomized, Double Blind, Placebo-Controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy in Patients with Resectable Gastric and GE Junction Cancer

Trial ID PCS6422G1-01
Sponsor ID Processa

A Phase 1b Dose-Escalation Study of the Safety and Pharmacokinetics of Fixed-Dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors

Trial ID 20189
Sponsor ID Incyte/ IQVIA

A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Principal Investigator
Ajay Dar, MD
Trial ID 8951-CL-0103
Sponsor ID 8951-CL-0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

Principal Investigator
Timothy A. McCarthy, MD
Trial ID 8951-CL0103
Sponsor ID 8951-CL0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression